SOLID BIOSCIENCES INC (SLDB)
US83422E2046 - Common Stock
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 38,508 restricted stock units (“RSUs”) to two newly hired employees.
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing...
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in...
Solid Biosciences files to sell 19.69M common shares for holders (NASDAQ:SLDB)
Solid Biosciences (SLDB) has filed a prospectus for the resale of 19.69M common shares, as indicated in a recent SEC filing.
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a...
Solid Biosciences stock rises on FDA orphan status
Solid Biosciences (SLDB) receives Orphan Drug Designation from the U.S. FDA for its treatment of Duchenne muscular dystrophy (DMD). Read more here.
Solid Biosciences raises $109M through private placement (NASDAQ:SLDB)
Solid Biosciences (SLDB) has entered into private placement to sell 16,973,103 shares of common stock at a price of $5.53 per share and, in lieu of common stock
Solid Biosciences Announces $109 Million Private Placement
CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...
Solid Biosciences receives FDA Fast Track designation for Duchenne gene therapy candidate
Iryna Drozd Solid Biosciences (NASDAQ:SLDB) rose about 9% in premarket trading as the company announced the receipt of Fast Track designation for the U.S.
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!
Solid Biosciences gets FDA okay for clinical testing of DMD gene therapy (SLDB)
Solid Biosciences (SLDB) stock rallied in after-hours trading on news the FDA had okayed clinical testing of the company's gene therapy for Duchenne muscular dystrophy.
Solid Biosciences to Participate at Jefferies London Healthcare Conference
CHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...
Solid Biosciences Provides Third Quarter Business Update and Financial Results
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 –